Efficacy and safety of the dual SGLT1 and 2 inhibitor sotagliflozin in combination with a mineralocorticoid receptor antagonist in patients hospitalized for worsening heart failure
Event:
Heart Failure 2023
Topic:
Pharmacotherapy
Session:
ePosters in chronic heart failure - pharmacotherapy 2